RxDoctor Payments Data

Mark Duca

Internal Medicine · Pittsburgh, PANPI 1023081445

Payments from drug & device makers

$483in general payments, 2019–2025

Across 24 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$240
  • Pfizer$63
  • E.r. Squibb & Sons, L.L.C.$46
  • Exact Sciences$44
  • Novo Nordisk$25
  • Lilly USA, LLC$21
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$483100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$483 in reported general payments places this provider in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$48,943
Medicare patients
224
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban237$141,163
OzempicSemaglutide86$84,573
EnbrelEtanercept11$79,803
JardianceEmpagliflozin106$56,748
XareltoRivaroxaban69$55,776
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$34,906
JanuviaSitagliptin Phosphate65$32,276
AranespDarbepoetin Alfa In Polysorbat17$27,856
OxycontinOxycodone Hcl15$14,262
MounjaroTirzepatide16$13,902
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$10,263
Atorvastatin Calcium761$9,319
TradjentaLinagliptin14$8,859
Aripiprazole15$7,467
Humalog Kwikpen U-200Insulin Lispro16$7,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$63$141,163237 claims
Novo NordiskOzempic$25$84,57386 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$240$45,35876 claims
Lilly USA, LLCMounjaro$21$13,90216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →